These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36176647)

  • 1. Learning Methodological Lessons from Exemplar Studies in Nephrology: PEXIVAS and Sample Size Calculation.
    Sandys V; Sexton DJ
    Kidney360; 2022 Aug; 3(8):1427-1430. PubMed ID: 36176647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size adjustment designs with time-to-event outcomes: A caution.
    Freidlin B; Korn EL
    Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical power and sample size calculations for time-to-event analysis.
    Zurakowski D; Staffa SJ
    J Thorac Cardiovasc Surg; 2023 Dec; 166(6):1542-1547.e1. PubMed ID: 36266091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD
    Trials; 2017 Feb; 18(1):83. PubMed ID: 28231813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choosing and changing the analysis scale in non-inferiority trials with a binary outcome.
    Li Z; Quartagno M; Böhringer S; van Geloven N
    Clin Trials; 2022 Feb; 19(1):14-21. PubMed ID: 34693789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.
    Li B; Grambsch P
    Clin Trials; 2006; 3(4):349-59. PubMed ID: 17060209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling competing risks in nephrology research: an example in peritoneal dialysis.
    Teixeira L; Rodrigues A; Carvalho MJ; Cabrita A; Mendonça D
    BMC Nephrol; 2013 May; 14():110. PubMed ID: 23705871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit.
    Deley MC; Ballman KV; Marandet J; Sargent D
    Clin Trials; 2012 Jun; 9(3):283-92. PubMed ID: 22569743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When do we need competing risks methods for survival analysis in nephrology?
    Noordzij M; Leffondré K; van Stralen KJ; Zoccali C; Dekker FW; Jager KJ
    Nephrol Dial Transplant; 2013 Nov; 28(11):2670-7. PubMed ID: 23975843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Power and sample size considerations in clinical trials with competing risk endpoints.
    Maki E
    Pharm Stat; 2006; 5(3):159-71. PubMed ID: 17080750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidences of obstetric outcomes and sample size calculations: A Danish national registry study based on all deliveries from 2008 to 2015.
    Hoegh S; Thellesen L; Christensen KB; Bergholt T; Hedegaard M; Sorensen JL
    Acta Obstet Gynecol Scand; 2020 Jan; 99(1):34-41. PubMed ID: 31370099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tutorial on using the paired t test for power calculations in repeated measures ANOVA with interactions.
    Langenberg B; Janczyk M; Koob V; Kliegl R; Mayer A
    Behav Res Methods; 2023 Aug; 55(5):2467-2484. PubMed ID: 36002625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Power of Low Back Pain Trials: A Systematic Review of Power, Sample Size, and Reporting of Sample Size Calculations Over Time, in Trials Published Between 1980 and 2012.
    Froud R; Rajendran D; Patel S; Bright P; Bjørkli T; Eldridge S; Buchbinder R; Underwood M
    Spine (Phila Pa 1976); 2017 Jun; 42(11):E680-E686. PubMed ID: 27792111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination-based sample size calculations for multivariable prognostic models for time-to-event data.
    Jinks RC; Royston P; Parmar MK
    BMC Med Res Methodol; 2015 Oct; 15():82. PubMed ID: 26459415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simulation-based sample size calculations of marginal proportional means models for recurrent events with competing risks.
    Furberg JF; Andersen PK; Scheike T; Ravn H
    Pharm Stat; 2024 Mar; ():. PubMed ID: 38509020
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.